Subject(s)
Autoantibodies , Myelin-Oligodendrocyte Glycoprotein , Optic Nerve Diseases , Humans , Male , Autoantibodies/immunology , Autoantibodies/blood , Diagnosis, Differential , Myelin-Oligodendrocyte Glycoprotein/immunology , Optic Nerve Diseases/immunology , Optic Nerve Diseases/etiology , Optic Neuritis/immunology , Optic Neuritis/diagnosis , AgedABSTRACT
The determinants of brown adipose tissue (BAT) activity are not yet known in detail but might serve as future therapeutic targets against obesity and the metabolic syndrome. We analyzed 235 datasets of lymphoma patients with two PET/CT examinations at different time points retrospectively. We assessed the anthropometric characteristics, features related to the metabolic syndrome, thyroid dysfunction, season of the PET/CT examination, weight change, prior cancer history, lymphoma subgroups, disease activity, and specific lymphoma-related therapies, and evaluated their association with BAT activity. We found BAT activity in 12% of all examinations, and the incidence of BAT activity after initially negative examinations was 10%. In multivariate regression analysis, the prevalence of BAT activity was associated with age, body mass index, sex, the season of the examination, diabetes mellitus, arterial hypertension, and medication on the beta-receptors. New BAT activity arose more often in patients without preceding lymphoma-related therapy. No specific medication was associated with BAT activity. In conclusion, this study confirms the potential connection of BAT with the metabolic syndrome. Preceding lymphoma-related therapy might have an inhibitory effect on the recruitment of BAT.
